8-K current report · filed Nov 16, 2026

STANDARD BIOTOOLS INC. (LAB) 8-K Current Report: November 16, 2026

Item 8.01LAB overview

Short answer

STANDARD BIOTOOLS INC. (LAB) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 8.01 (Other Events). Merger vote remains scheduled for November 19, 2026, with SEC-effective proxy materials supplemented before stockholder approval.

STANDARD BIOTOOLS INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • Merger vote remains scheduled for November 19, 2026, with SEC-effective proxy materials supplemented before stockholder approval
  • 15 demand letters and two shareholder lawsuits allege material omissions, creating litigation, delay and transaction-cost risks
  • Supplemental Centerview analysis values Standard BioTools liquidation at approximately $468 million, or $1.14 per share
  • Centerview’s Treeline DCF implies $3,040 million to $4,205 million equity value, or $15.88 to $21.89 per share
  • UBS’ Treeline DCF implies $2,638 million to $3,313 million equity value, or $13.59 to $17.07 per share

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other STANDARD BIOTOOLS INC. 8-K filings

Get the next LAB 8-K as it lands

Follow LAB for push alerts, or ask the research agent what this filing means.